That’s completely incorrect and incidentally the psi-GAD program has nothing to do with Sud Agarwal.
Do yourself a favor and speak to the board. Sud Agarwal certainly has a skill in identifying novel opportunities. IHL-675A was one of these ideas and ironically it may well be a unicorn for the company. However, Sud Agarwal has no clinical, or drug development experience. These are factual statements which you can verify.
On the contrary, have you met or researched Bob Clark? This is not some unknown person in FDA drug development.
IHL Price at posting:
6.7¢ Sentiment: Buy Disclosure: Held
